Document › Details

UCB S.A.. (2/28/19). "Press Release: UCB Full Year Report 2018. 2018 Marks the Fifth Consecutive Year of Profitable Growth, Intensifying Investment in UCB’s Strong Pipeline". Brussels.

	Organisation	UCB S.A. (Euronext: UCB)
	Group	UCB (Group)
	Product	Cimzia®
	Product 2	Vimpat®
	Person	Tellier, Jean-Christophe (201403– CEO-elect joined UCB 2011 before Ipsen + Macrogenics + Novartis)
	Person 2	Witte, Antje (UCB 201601 Investor Relations)

Original document
accessed by [iito] on 2019-03-01

Record changed: 2019-03-06

More documents for UCB (Group)

[1] Rinri Therapeutics Ltd.. (5/20/19). "Press Release: Rinri Therapeutics Secures £1.4 Million Seed Funding to Advance Its Novel Regenerative Cell Therapy to Treat Sensorineural Hearing Loss". Sheffield....
[2] UCB S.A.. (4/9/19). "Press Release: FDA Approves Evenity (Romosozumab) for the Treatment Of Osteoporosis in Postmenopausal Women at High Risk for Fracture". Brussels....
[3] UCB S.A.. (3/1/19). "Press Release: New Data Affirms Strength of UCB Immuno-Dermatology Portfolio". Brussels....
[4] UCB S.A.. (2/15/19). "Press Release: UCB Builds on Its R&D Footprint to Form a Research Satellite Facility within King’s College London". Brussels & Slough....
[5] UCB S.A.. (2/11/19). "Press Release: UCB and Epilepsy Society Announce Pioneering UK Genomics R&D collaboration". Slough & Brussels....
[6] UCB S.A.. (7/13/18). "Press Release: UCB and Amgen Resubmit Biologics Licence Application (BLA) for Evenity (Romosozumab) to the U.S. FDA". Brussels & Thousand Oaks, CA....
[7] StrideBio, Inc.. (6/13/18). "Press Release: StrideBio Closes $15.7 Million Series A Financing to Advance Transformational AAV Platform". Durham, NC....
[8] Science 37 Inc.. (5/3/18). "Press Release: Science 37 Partners with UCB to Fundamentally Change the Clinical Trial Ecosystem, Focusing on More Patient-Friendly, Technology-Enabled Trials at Home". Playa Vista, CA....
[9] UCB S.A.. (4/27/18). "Press Release: UCB Announces Positive CHMP Opinion for Cimzia (certolizumab pegol) in Patients with Moderate-to-Severe Plaque Psoriasis". Brussels....
[10] UCB S.A.. (4/25/18). "Press Release: UCB First Three Months Interim Report 2018. UCB Tracking Well towards Full Year Financial Outlook". Brussels....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

» top